Alopecia Areata Barbae in a Nutshell

Novel Treatments – Review Article

Nwosu A. · Miteva M.

Author affiliations

Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Novel Treatments – Review Article

Received: August 08, 2022
Accepted: January 22, 2023
Published online: March 08, 2023

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 1

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD

Abstract

Beard alopecia areata, or alopecia areata barbae, (BAA) is a subset of alopecia areata, a T-cell mediated inflammatory disease that disrupts the hair follicle cycle leading to early onset of catagen. The aim of this review is to help strengthen clinicians' skills in the evaluation, diagnosis, and management of BAA. We performed a literature review according to the modified PRISMA guidelines, using a combination of relevant key words in electronic databases. According to the data from the 25 articles on BAA reviewed here, BAA mostly affects middle-aged men (mean age 31 years) who typically experience patchy hair loss in the neck region, which spreads to the scalp within 12 months. Similar to AA, BAA is associated with autoimmune diseases such as H. pylori and thyroiditis; however, BAA has no clear genetic pattern of inheritance which is observed in alopecia areata. Common dermoscopic findings in BAA include vellus white hairs and exclamation mark hairs, which may help distinguish it from other pathologies affecting facial hair. In clinical trials, the ALBAS tool offers clinicians an objective metric to evaluate BAA severity. Until recently, topical steroids have been the mainstay therapy; however, topical and oral janus kinase inhibitors are achieving improved results, with up to 75% beard regrowth in an average of 12 months.

© 2023 S. Karger AG, Basel

References Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403. Harries MJ, Sun J, Paus R, LE K Jr. Management of alopecia areata. BMJ. 2010;Vol. 341. p. c3671. Hunt N, McHale S. Reported experiences of persons with alopecia areata. J Loss Trauma. 2004;10(1):33–50. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG; British Association of Dermatologists. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149(4):692–9. Cervantes J, Fertig RM, Maddy A, Tosti A. Alopecia areata of the beard: a review of the literature. Am J Clin Dermatol. 2017;18(6):789–96. Glynn L. EBLIP critical appraisal checklist. St. John’s. Memorial University of Newfoundland. Available from: http://ebltoolkit.pbworks.com/f/EBLCriticalAppraisalChecklist.pdf. Maurer M, Rietzler M, Burghardt R, Siebenhaar F. The male beard hair and facial skin: challenges for shaving. Int J Cosmet Sci. 2016;38(Suppl 1):3–9. Langbein L, Yoshida H, Praetzel-Wunder S, Parry DA, Schweizer J. The keratins of the human beard hair medulla: the riddle in the middle. J Invest Dermatol. 2010;130(1):55–73. Morioka M. The Medulla. In: Hair follicle: differentiation under the electron microscope : an atlas account. Japan: Springer; 2005. Vogt A, McElwee KJ, Blume-Peytavi U, Tosti A, Trüeb RM. The biology of the hair follicle. In: Blume-Peytavi U, Tosti A, Trüeb R, editors. Hair growth disord. Berlin, Heidelberg: Springer; 2008. p. 1–22. Tobin DJ, Orentreich N, Fenton DA, Bystryn JC. Antibodies to hair follicles in alopecia areata. J Invest Dermatol. 1994;102(5):721–4. Tobin DJ, Bystryn JC. Immunity to hair follicles in alopecia areata. J Invest Dermatol. 1995;104(5 Suppl):13S–14S. Tobin DJ, Fenton DA, Kendall MD. Ultrastructural observations on the hair bulb melanocytes and melanosomes in acute alopecia areata. J Invest Dermatol. 1990;94(6):803–7. Winter H, Schissel D, Parry DAD, Smith TA, Liovic M, Birgitte Lane E, et al. An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae. J Invest Dermatol. 2004;122(3):652–7. Ogunbiyi A. Pseudofolliculitis barbae; current treatment options. Clin Cosmet Investig Dermatol. 2019;12:241–7. Courtois M, Loussouarn G, Hourseau S, Grollier JF. Periodicity in the growth and shedding of hair. Br J Dermatol. 1996;134(1):47–54. Rutberg SE, Kolpak ML, Gourley JA, Tan G, Henry JP, Shander D. Differences in expression of specific biomarkers distinguish human beard from scalp dermal papilla cells. J Invest Dermatol. 2006 Dec;126(12):2583–95. Thornton MJ, Hamada K, Messenger AG, Randall VA. Androgen-dependent beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells. J Invest Dermatol. 1998;111(5):727–32. Randall VA. Androgens and human hair growth. Clin Endocrinol. 1994 Apr;40(4):439–57. Randall VA. Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cel Dev Biol. 2007;18(2):274–85. Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol. 2013;2013:348546. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594–600. Azzawi S, Penzi LR, Senna MM. Immune privilege collapse and alopecia development: is stress a factor. Skin Appendage Disord. 2018;4:236–44. Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players. Immunotargets Ther. 2021;10:299–312. Ito T. Hair follicle is a target of stress hormone and autoimmune reactions. J Dermatol Sci. 2010;60(2):67–73. Cerwenka A, Swain SL. TGF-beta1: immunosuppressant and viability factor for T lymphocytes. Microbes Infect. 1999;1(15):1291–6. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev. 2006;213:213–27. Foitzik K, Lindner G, Mueller-Roever S, Maurer M, Botchkareva N, Botchkarev V, et al. Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J. 2000;14(5):752–60. Żeberkiewicz M, Rudnicka L, Malejczyk J. Immunology of alopecia areata. Cent Eur J Immunol. 2020;45(3):325–33. Bhandary DJ, Girisha BS, Mahadevappa BN. Clinico-dermoscopic pattern of beard alopecia areata: a cross-sectional study. Indian Dermatol Online J. 2019;10(6):644–9. McElwee KJ, Gilhar A, Tobin DJ, Ramot Y, Sundberg JP, Nakamura M, et al. What causes alopecia areata? Exp Dermatol. 2013;22(9):609–26. Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezhad A. Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol. 2005;Vol. 5. 11. Campuzano-Maya G. Cure of alopecia areata after eradication of Helicobacter pylori: a new association? World J Gastroenterol. 2011;17(26):3165–70. Saceda-Corralo D, Grimalt R, Fernández-Crehuet P, Clemente A, Bernardez C, Garcia-Hernandez MJ, et al. Beard alopecia areata: a multicentre review of 55 patients. J Eur Acad Dermatol Venereol. 2017;31(1):187–92. AlGaadi S, Miteva M, Tosti A. Frontal fibrosing alopecia in a male presenting with sideburn loss. Int J Trichology. 2015;7(2):72–3. Fernandez-Flores A, Saeb-Lima M, Cassarino DS. Histopathology of aging of the hair follicle. J Cutan Pathol. 2019;46(7):508–19. Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: new approaches, new findings, new treatments. J Dermatol Sci. 2015;78(1):11–20. Petukhova L, Cabral RM, Mackay-Wiggan J, Clynes R, Christiano AM. The genetics of alopecia areata: what’s new and how will it help our patients? Dermatol Ther. 2011;24(3):326–36. Olsen EA, Roberts J, Sperling L, Tosti A, Shapiro J, McMichael A, et al. Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018;79(3):470–8.e3. Stefanis AJ, Arenberger P, Arenbergerova M, Gkalpakiotis S. Alopecia barbae severity score: a novel scoring system to estimate the extent of beard loss and success of treatment [published online ahead of print. Br J Dermatol. 2021;10. Narisawa Y, Hashimoto K, Kohda H. Epithelial skirt and bulge of human facial vellus hair follicles and associated Merkel cell-nerve complex. Arch Dermatol Res. 1993;285(5):269–77. Trautman S, Thompson M, Roberts J, Thompson CT. Melanocytes: a possible autoimmune target in alopecia areata. J Am Acad Dermatol. 2009;61(3):529–30. Forouzan P, Cohen PR. Incipient diabetes mellitus and nascent thyroid disease presenting as beard alopecia areata: case report and treatment review of alopecia areata of the beard. Cureus. 2020;12(7):e9500. Durdu M, Özcan D, Baba M, Seçkin D. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol. 2015;72(4):640–50. Murad A, Bergfeld W. Treatment for facial alopecia areata: a systematic review with evidence-based analysis. J Am Acad Dermatol. 2018;78(3):601–5. Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata. Dermatol Surg. 2007;33(12):1483–7. Rangwala S, Rashid RM. Alopecia: a review of laser and light therapies. Dermatol Online J. 2012;18(2):3. King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–99. Rubin R. First systemic treatment for severe alopecia is approved. JAMA. 2022;328(3):235. Kerkemeyer KLS, John JM, Sinclair R, Bhoyrul B. Response of alopecia areata of the beard to oral tofacitinib. J Am Acad Dermatol. 2020;82(5):1228–30. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–8. Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323–35. Kerkemeyer KLS, Sinclair RD, Bhoyrul B. Topical tofacitinib for the treatment of alopecia areata affecting facial hair. Br J Dermatol. 2021;185(3):677–9. Ramot Y, Zlotogorski A. Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Skin Appendage Disord. 2018;4(2):122–4. Pototschnig H, Madl MT. Successful treatment of alopecia areata barbae with platelet-rich plasma. Cureus. 2020;12(4):e7495. Tazi-Ahnini R, Cork MJ, Wengraf D, Wilson AG, Gawkrodger DJ, Birch MP, et al. Notch4, a non-HLA gene in the MHC is strongly associated with the most severe form of alopecia areata. Hum Genet. 2003;112(4):400–3. Mathieu M, Cotta-Grand N, Daudelin JF, Thébault P, Labrecque N. Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. Immunol Cel Biol. 2013;91(1):82–8. Sterkens AL, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21(2):215–30. Arnold AW, Buechner SA. Keratosis pilaris and keratosis pilaris atrophicans faciei. J Dtsch Dermatol Ges. 2006;4(4):319–23. Bomfim ICC, Ianhez M, Miot HA. Dermatoscopic findings of syphilitic alopecia. Bras Dermatol. 2020;95(4):518–20. Cutrone M, Grimalt R. The dermoscopic “pluck out sign” for beard trichotillomania. Skin Appendage Disord. 2018;4(1):15–7. Kwong RA, Kossard S. Alopecia areata masquerading as frontal fibrosing alopecia. Australas J Dermatol. 2006;47(1):63–6. Ocampo-Garza SS, Vastarella M, Ocampo-Candiani J, Cantelli M, Miano C, Nappa P, et al. Trichoscopy of the beard: aid tool for diagnosis of frontal fibrosing alopecia in men. JAAD Case Rep. 2021;Vol. 15. p. 104–6. Gómez-Moyano E, Martínez Pilar L, Vera Casaño A, Martín González T, Moyano Almagro B, Fernandez Ballesteros MD, et al. Correlation between dermoscopy and direct microscopy in Tinea barbae. J Mycol Med. 2021;31(1):101104. Zvulunov A, Shkalim V, Ben-Amitai D, Feinmesser M. Clinical and histopathologic spectrum of alopecia mucinosa/follicular mucinosis and its natural history in children. J Am Acad Dermatol. 2012;67(6):1174–81. Ermertcan AT, Öztürkcan S, Şahin MT, Türkdogan P, Saçar T. Erythromelanosis follicularis faciei et colli associated with keratosis pilaris in two brothers. Pediatr Dermatol. 2006;23(1):31–4. Jordaan HF, Louw M. The moth-eaten alopecia of secondary syphilis a histopathological study of 12 patients. Am J Dermatopathol. 1995;17(2):158–62. Bergfeld W, Mulinari-Brenner F, McCarron K, Embi C. The combined utilization of clinical and histological findings in the diagnosis of trichotillomania. J Cutan Pathol. 2002;29(4):207–14. Wong D, Goldberg LJ. The depth of inflammation in frontal fibrosing alopecia and lichen planopilaris: a potential distinguishing feature. J Am Acad Dermatol. 2017;76(6):1183–4. Shurman D, Benedetto A, Benedetto E. American Society for Laser Medicine and Surgery Twenty-Ninth Annual Conference April 1–5, 2009 Abstracts. Hoboken: Wiley Online Library; 2009. https://doi.org/10.1002/lsm.20783. Kuruvella K, Shivlal P. Tinea barbae. Tampa: StatPearls; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563204/. Article / Publication Details

First-Page Preview

Abstract of Novel Treatments – Review Article

Received: August 08, 2022
Accepted: January 22, 2023
Published online: March 08, 2023

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 1

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif